Physics of Proton Therapy Treatment Planning

Author(s):  
В. Климанов ◽  
V. Klimanov ◽  
А. Самойлов ◽  
A. Samoylov ◽  
А. Гаджинов ◽  
...  

The most important stage of radiation therapy of oncological diseases is the planning of radiation treatment. In this work, this complex process in relation to proton therapy is proposed to be divided into medical and physical planning. In conventional therapy with photons and electrons, the latter is usually called dosimetric planning, however, when applied to proton radiation therapy, this stage involves a significantly wider range of tasks related to the modification and scanning of the proton beam, spreading and compensation of ranges, taking into account when planning for uncertainties and finiteness of proton ranges, a decrease in the contribution to the dose of secondary neutrons, the creation of error-tolerant optimization algorithms for dosimetric plans, and, finally, a precision calculation of dose distributions. The paper discusses the main stages and problems of physical planning of proton radiation therapy. Particular attention is paid to the formation of an extended high-dose region (extended Bragg peak) using the beam scattering method and scanning method, and to the algorithms for calculating the dose distributions created by protons in the scattering and beam scanning systems. The most detailed consideration is given to different versions of the proton pencil beam method, which allows to increase the dose calculation accuracy and take into account the transverse scattering and fluctuations in proton energy losses, especially at the end of the path (halo effect), analytical and numerical methods. Scanning are divided into three main technologies: homogeneous scanning, single field uniform dose (SFUD), multi-field uniform dose (MFUD), often called intensity modulated proton therapy (IMPT). Actual accounting problems are considered when planning the irradiation of the movement of organs, and uncertainties in determining path lengths and optimization of irradiation plans. In particular features, problems and modern approaches to the optimization of dosimetry plans of proton radiation therapy are discussed. It is noted that one of the most promising practical solutions for the uncertainty management in determining the path lengths of protons in optimization is to include possible errors in the objective function of the optimization algorithm. This technique ensures that an optimized irradiation plan will more reliably protect normal tissues and critical organs adjacent to the irradiation target from overexposure.

2009 ◽  
Vol 16 (12) ◽  
pp. 1641-1643 ◽  
Author(s):  
Hiroshi Ooba ◽  
Tatsuya Abe ◽  
Tohru Kamida ◽  
Mitsuhiro Anan ◽  
Yasutomo Momii ◽  
...  

Author(s):  
А. Самойлов ◽  
A. Samoylov ◽  
Ж. Смирнова ◽  
Zh. Smirnova ◽  
В. Климанов ◽  
...  

This paper analyzes the current state of clinical application of proton radiation therapy (PRT) for the treatment of cancer. In particular, the indications for the use of PRT for the treatment of specific pathologies, the results and condition of randomized clinical studies of PRT compared to photon radiation therapy (PhRT) are considered, the cost of PRT is compared with the cost of PhRT. The focus is on discussing the results of PRT using in advanced countriesand Russia for the treatment of several common tumor sites. In the conclusion of the work, the ways of further improvement of radiobiology, dose delivering technology and dosimetric support of PRT are considered.


Author(s):  
Lyudmila Viktorovna Sotnikova

The article deals with the features of reflection in the accounting of organizations that are manufacturers of expensive medical equipment, the transfer of this medical equipment to non-operational (financial) lease to medical organizations. The article reviews the possibilities of proton therapy, manufacturers of equipment for proton therapy, including Russian ones. It is Russian manufacturers who are actively working on the development of compact proton accelerator samples that can be placed in any, not only specialized medical organizations. The article presents an example of accounting for accounting objects (revenue, cost, financial result (profit/loss)) arising on the date of conclusion of the contract of non-operational (financial) lease of equipment for proton radiation therapy.


2020 ◽  
Vol 93 (1107) ◽  
pp. 20190359 ◽  
Author(s):  
Andries N. Schreuder ◽  
Jacob Shamblin

Proton radiation therapy has been used clinically since 1952, and major advancements in the last 10 years have helped establish protons as a major clinical modality in the cancer-fighting arsenal. Technologies will always evolve, but enough major breakthroughs have been accomplished over the past 10 years to allow for a major revolution in proton therapy. This paper summarizes the major technology advancements with respect to beam delivery that are now ready for mass implementation in the proton therapy space and encourages vendors to bring these to market to benefit the cancer population worldwide. We state why these technologies are essential and ready for implementation, and we discuss how future systems should be designed to accommodate their required features.


1999 ◽  
Vol 91 (3) ◽  
pp. 432-439 ◽  
Author(s):  
Eugen B. Hug ◽  
Lilia N. Loredo ◽  
Jerry D. Slater ◽  
Alexander Devries ◽  
Roger I. Grove ◽  
...  

Object. Local tumor control, patient survival, and treatment failure outcomes were analyzed to assess treatment efficacy in 58 patients in whom fractionated proton radiation therapy (RT) was administered for skull base chordomas and chondrosarcomas.Methods. Between March 1992 and January 1998, a total of 58 patients who could be evaluated were treated for skull base tumors, 33 for chordoma and 25 for chondrosarcoma. Following various surgical procedures, residual tumor was detected in 91% of patients; 59% demonstrated brainstem involvement. Target dosages ranged from 64.8 and 79.2 (mean 70.7) Co Gy equivalent. The range of follow up was 7 to 75 months (mean 33 months).In 10 patients (17%) the treatment failed locally, resulting in local control rates of 92% (23 of 25 patients) for chondrosarcomas and 76% (25 of 33 patients) for chordomas. Tumor volume and brainstem involvement influenced control rates. All tumors with volumes of 25 ml or less remained locally controlled, compared with 56% of tumors larger than 25 ml (p = 0.02); 94% of patients without brainstem involvement did not experience recurrence; in patients with brainstem involvement (and dose reduction because of brainstem tolerance constraints) the authors achieved a tumor control rate of 53% (p = 0.04). Three patients died of their disease, and one died of intercurrent disease. Actuarial 5-year survival rates were 100% for patients with chondrosarcoma and 79% for patients with chordoma. Grade 3 and 4 late toxicities were observed in four patients (7%) and were symptomatic in three (5%).Conclusions. High-dose proton RT offers excellent chances of lasting tumor control and survival, with acceptable risks. In this series all small- and medium-sized tumors with no demonstrable brainstem involvement have been controlled; all such patients are alive. Surgical debulking enhanced delivery of full tumoricidal doses, but even patients with large tumors and disease abutting crucial normal structures benefited.


2020 ◽  
Vol 93 (1107) ◽  
pp. 20190845 ◽  
Author(s):  
Tonghe Wang ◽  
Jun Zhou ◽  
Sibo Tian ◽  
Yinan Wang ◽  
Pretesh Patel ◽  
...  

Objectives: The purpose of this study is to investigate the dosimetric effect and clinical impact of delivering a focal radiotherapy boost dose to multiparametric MRI (mp-MRI)-defined dominant intraprostatic lesions (DILs) in prostate cancer using proton therapy. Methods: We retrospectively investigated 36 patients with pre-treatment mp-MRI and CT images who were treated using pencil beam scanning (PBS) proton radiation therapy to the whole prostate. DILs were contoured on co-registered mp-MRIs. Simultaneous integrated boost (SIB) plans using intensity-modulated proton therapy (IMPT) were created based on conventional whole-prostate-irradiation for each patient and optimized with additional DIL coverage goals and urethral constraints. DIL dose coverage and organ-at-risk (OAR) sparing were compared between conventional and SIB plans. Tumor control probability (TCP) and normal tissue complication probability (NTCP) were estimated to evaluate the clinical impact of the SIB plans. Results: Optimized SIB plans significantly escalated the dose to DILs while meeting OAR constraints. SIB plans were able to achieve 125, 150 and 175% of prescription dose coverage in 74, 54 and 17% of 36 patients, respectively. This was modeled to result in an increase in DIL TCP by 7.3–13.3% depending on [Formula: see text] and DIL risk level. Conclusion: The proposed mp-MRI-guided DIL boost using proton radiation therapy is feasible without violating OAR constraints and demonstrates a potential clinical benefit by improving DIL TCP. This retrospective study suggested the use of IMPT-based DIL SIB may represent a strategy to improve tumor control. Advances in knowledge: This study investigated the planning of mp-MRI-guided DIL boost in prostate proton radiation therapy and estimated its clinical impact with respect to TCP and NTCP.


Sign in / Sign up

Export Citation Format

Share Document